Recommended Adult Immunization Schedule --- United States,
October 2006--September 2007
The Recommended Adult Immunization Schedule has been approved by the Advisory Committee on Immunization Practices, the American College of Obstetricians and Gynecologists, and
the American Academy of Family Physicians. The standard
MMWR footnote format has been modified for publication of this schedule.
Suggested citation: Centers for Disease Control and Prevention. Recommended
Adult Immunization Schedule---United States, October
2006--September 2007. MMWR 2006;55:Q1--Q4.
The Advisory Committee on Immunization Practices (ACIP) annually reviews the recommended Adult
Immunization Schedule to ensure that the schedule reflects current recommendations for the licensed vaccines. In June 2006, ACIP
approved the Adult Immunization Schedule for October 2006--September 2007. This schedule has also been approved by the
American Academy of Family Physicians and the American
College of Obstetricians and Gynecologists.
Changes in the Schedule for October 2006--September 2007
The 2006--2007 schedule differs from the previous
schedule as follows:
The broken red line has been deleted on the age-based schedule (Figure 1). Vaccination of persons with specific
risk factors is now shown only with purple bars.
Human papillomavirus (HPV) vaccine has been added to the age-based schedule, with a yellow bar indicating that
the vaccine is recommended for women <26 years.
Tetanus, diphtheria, and acellular pertussis (Tdap)
vaccine has been added to the age-based schedule, with a
hatched yellow bar indicating that Tdap is a one-time,
1-dose recommendation for persons <64 years.
The purple bar for varicella vaccine has been shortened in anticipation of the recommendation for the use of
zoster vaccine in persons aged >60 years.
A new column has been added to the medical/other indications schedule (Figure 2) to clarify indications for hepatitis
A and B vaccines. The indications "chronic liver disease" and "recipients of clotting factor concentrates" have been
removed from the previous schedule's third and fifth columns, respectively, and combined into a new column. The column has
a yellow bar for hepatitis A and B vaccines, clarifying that these vaccines are recommended for all persons with
these medical indications.
HPV vaccine has been added to the medical/other indications schedule, with a yellow bar to indicate the vaccine
is recommended for women aged <26 years with all
indications except pregnancy.
Tdap was added to the medical/other indications schedule, with a hatched yellow bar to indicate that Tdap is a
one-time, 1-dose recommendation for all indications
except pregnancy.
The tetanus and diphtheria footnote (#1) has been
reworded to reflect ACIP recommendations for use of Tdap.
A footnote (#2) has been added to reflect ACIP recommendations for HPV vaccination for all women aged
<26 years.
The measles, mumps, and rubella (MMR) footnote (#3) has been reworded to reflect ACIP recommendations
to administer a second dose of mumps vaccine to adults in certain age groups and with certain risk factors.
The varicella footnote (#4) has been reworded in accordance with ACIP recommendations for administering a
routine second dose for all adults without evidence of immunity. The footnote also has been revised to reflect the new
definition of immunity to varicella.
The influenza footnote (#5) has been revised to reflect recent ACIP recommendations to vaccinate close contacts
of children aged 0--59 months rather than 0--23 months
(1).
The hepatitis B footnote (#9) has been revised to reflect recommendations to vaccinate any adult seeking protection
from hepatitis B virus infection and vaccinate adults
in specific settings (e.g., sexually transmitted disease clinics)
(2).
<>
The Adult Immunization Schedule is available in English and Spanish at
http://www.cdc.gov/nip/recs/adult-schedule.htm. General information about adult vaccinations, including recommendations concerning vaccination of person with HIV
and other immunosuppressive conditions, is available from state and local health departments and at
http://www.cdc.gov/nip. Vaccine information statements are available at
http://www.cdc.gov/nip/publications/vis. ACIP statements for each
recommended vaccine and provisional vaccine recommendations can be viewed, downloaded, and printed at
http://www.cdc.gov/nip/publications/acip-list.htm. Instructions for reporting adverse events to the Vaccine Adverse Event Reporting System
are available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.
CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of
the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR. In
press2006.
Return to top.
1. Tetanus, diphtheria, and acellular pertussis (Td/Tdap)
vaccination. Adults with uncertain histories of a complete primary vaccination
series with diphtheria and tetanus toxoid_containing vaccines should begin or complete a primary vaccination series. A primary series for adults is
3 doses; administer the first 2 doses at least 4 weeks apart and the third dose 6_12 months after the second. Administer a booster dose to
adults who have completed a primary series and if the last vaccination was received
>10 years previously. Tdap or tetanus and diphtheria (Td)
vaccine may be used; Tdap should replace a single dose of Td for adults aged <65 years who have not previously received a dose of Tdap (either in
the primary series, as a booster, or for wound management). Only one of two Tdap products
(Adacel® [sanofi pasteur, Swiftwater, Pennsylvania])
is licensed for use in adults. If the person is pregnant and received the last Td vaccination
>10 years previously, administer Td during the second
or third trimester; if the person received the last Td vaccination in <10 years, administer Tdap during the immediate postpartum period. A
one-time administration of 1-dose of Tdap with an interval as short as 2 years from a previous Td vaccination is recommended for postpartum
women, close contacts of infants aged <12 months, and all health-care workers with direct patient contact. In certain situations, Td can be deferred
during pregnancy and Tdap substituted in the immediate postpartum period, or Tdap can be given instead of Td to a pregnant woman after an
informed discussion with the woman (see
http://www.cdc.gov/nip/publications/acip-list.htm). Consult the ACIP statement for recommendations
for administering Td as prophylaxis in wound management (http://www.cdc.gov/mmwr/preview/mmwrhtml/00041645.htm).
2. Human papillomavirus (HPV)
vaccination. HPV vaccination is recommended for all women aged
<26 years who have not completed the vaccine series. Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, women who
are sexually active should still be vaccinated. Sexually active women who have not been infected with any of the HPV vaccine types receive the
full benefit of the vaccination. Vaccination is less beneficial for women who have already been infected with one or more of the four HPV
vaccine types. A complete series consists of 3 doses. The second dose should be administered 2 months after the first dose; the third dose should
be administered 6 months after the first dose. Vaccination is not recommended during pregnancy. If a woman is found to be pregnant after
initiating the vaccination series, the remainder of the 3-dose regimen should be delayed until after completion of the pregnancy.
3. Measles, mumps, rubella (MMR) vaccination.
Measles component: adults born before 1957 can be considered immune to measles.
Adults born during or after 1957 should receive
>1 dose of MMR unless they have a medical contraindication, documentation of
>1 dose, history of measles based on health-care provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who
1) have been recently exposed to measles or in an outbreak setting; 2) have been previously vaccinated with killed measles vaccine; 3) have
been vaccinated with an unknown type of measles vaccine during 1963_1967; 4) are students in postsecondary educational institutions; 5) work in
a health-care facility; or 6) plan to travel internationally. Withhold MMR or other measles-containing vaccines from HIV-infected persons with
severe immunosuppression. Mumps component: adults born before 1957 can generally be considered immune to mumps. Adults born during or
after 1957 should receive 1 dose of MMR unless they have a medical contraindication, history of mumps based on health-care provider diagnosis,
or laboratory evidence of immunity. A second dose of MMR is recommended for adults who 1) are in an age group that is affected during a
mumps outbreak; 2) are students in postsecondary educational institutions; 3) work in a health-care facility; or 4) plan to travel internationally.
For unvaccinated health-care workers born before 1957 who do not have other evidence of mumps immunity, consider giving 1 dose on a
routine basis and strongly consider giving a second dose during an outbreak.
Rubella component: administer 1 dose of MMR vaccine to women
whose rubella vaccination history is unreliable or who lack laboratory evidence of immunity. For women of childbearing age, regardless of birth
year, routinely determine rubella immunity and counsel women regarding congenital rubella syndrome. Do not vaccinate women who are pregnant
or who might become pregnant within 4 weeks of receiving vaccine. Women who do not have evidence of immunity should receive MMR
vaccine upon completion or termination of pregnancy and before discharge from the health-care facility.
4. Varicella vaccination. All adults without evidence of immunity to varicella should receive 2 doses of varicella vaccine. Special
consideration should be given to those who 1) have close contact with persons at high risk for severe disease (e.g., health-care workers and family contacts
of immunocompromised persons) or 2) are at high risk for exposure or transmission (e.g., teachers of young children; child care employees;
residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living
in households with children; non-pregnant women of childbearing age; and international travelers). Evidence of immunity to varicella in adults
includes any of the following: 1) documentation of 2 doses of varicella vaccine at least 4 weeks apart; 2) U.S.-born before 1980 (although for
health-care workers and pregnant women, birth before 1980 should not be considered evidence of immunity); 3) history of varicella based on diagnosis
or verification of varicella by a health-care provider (for a patient reporting a history of or presenting with an atypical case, a mild case, or both,
health-care providers should seek either an epidemiologic link with a typical varicella case or evidence of laboratory confirmation, if it was performed at
the time of acute disease); 4) history of herpes zoster based on health-care provider diagnosis; or 5) laboratory evidence of immunity or
laboratory confirmation of disease. Do not vaccinate women who are pregnant or might become pregnant within 4 weeks of receiving the vaccine.
Assess pregnant women for evidence of varicella immunity. Women who do not have evidence of immunity should receive dose 1 of varicella vaccine
upon completion or termination of pregnancy and before discharge from the health-care facility. Dose 2 should be
administered 4_8 weeks after dose 1.
5. Influenza vaccination. Medical
indications: chronic disorders of the cardiovascular or pulmonary systems, including asthma;
chronic metabolic diseases, including diabetes mellitus, renal dysfunction, hemoglobinopathies, or immunosuppression (including
immuno-suppression caused by medications or HIV); any condition that compromises respiratory function or the handling of respiratory secretions or that can
increase the risk of aspiration (e.g., cognitive dysfunction, spinal cord injury, or seizure disorder or other neuromuscular disorder); and pregnancy
during the influenza season. No data exist on the risk for severe or complicated influenza disease among persons with asplenia; however, influenza is
a risk factor for secondary bacterial infections that can cause severe disease among persons with asplenia.
Occupational indications: health-care workers and employees of long-term_care and assisted living facilities.
Other indications: residents of nursing homes and other
long-term_care and assisted living facilities; persons likely to transmit influenza to persons at high risk (i.e., in-home household contacts and caregivers
of children aged 0_59 months, or persons of all ages with high-risk conditions); and anyone who would like to be vaccinated. Healthy,
nonpregnant persons aged 5_49 years without high-risk medical conditions who are not contacts of severely immunocompromised persons in special
care units can receive either intranasally administered influenza vaccine
(FluMist®) or inactivated vaccine. Other persons should receive
the inactivated vaccine.
6. Pneumococcal polysaccharide vaccination.
Medical indications: chronic disorders of the pulmonary system (excluding
asthma); cardiovascular diseases; diabetes mellitus; chronic liver diseases, including liver disease as a result of alcohol abuse (e.g., cirrhosis);
chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy [if elective splenectomy is
planned, vaccinate at least 2 weeks before surgery]); immunosuppressive conditions (e.g., congenital immunodeficiency, HIV infection [vaccinate as
close to diagnosis as possible when CD4 cell counts are highest], leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized
malignancy, or organ or bone marrow transplantation); chemotherapy with alkylating agents, antimetabolites, or high-dose, long-term corticosteroids;
and cochlear implants. Other indications: Alaska Natives and certain American Indian populations and residents of nursing homes or other
long-term_care facilities.
7. Revaccination with pneumococcal polysaccharide vaccine.
One-time revaccination after 5 years for persons with chronic renal failure
or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy); immunosuppressive conditions (e.g.,
congenital immunodeficiency, HIV infection, leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized malignancy, or organ or bone
marrow transplantation); or chemotherapy with alkylating agents, antimetabolites, or high-dose, long-term corticosteroids. For persons aged
>65 years, one-time revaccination if they were vaccinated
>5 years previously and were aged <65 years at the time of primary vaccination.
8. Hepatitis A vaccination. Medical
indications: persons with chronic liver disease and persons who receive clotting factor
concentrates. Behavioral indications: men who have sex with men and persons who use illegal drugs.
Occupational indications: persons working with
hepatitis A virus (HAV)_infected primates or with HAV in a research laboratory setting.
Other indications: persons traveling to or working in countries
that have high or intermediate endemicity of hepatitis A (a list of countries is available at
http://www.cdc.gov/travel/diseases.htm) and any person
who would like to obtain immunity. Current vaccines should be administered in a 2-dose schedule at either 0 and 6_12 months, or 0 and 6_18
months. If the combined hepatitis A and hepatitis B vaccine is used, administer 3 doses at 0, 1, and 6 months.
9. Hepatitis B vaccination.Medical
indications: persons with end-stage renal disease, including patients receiving hemodialysis;
persons seeking evaluation or treatment for a sexually transmitted disease (STD); persons with HIV infection; persons with chronic liver disease;
and persons who receive clotting factor concentrates.
Occupational indications: health-care workers and public-safety workers who are exposed
to blood or other potentially infectious body fluids.
Behavioral indications: sexually active persons who are not in a long-term, mutually
monogamous relationship (i.e., persons with >1 sex partner during the previous 6 months); current or recent injection-drug users; and men who have sex
with men. Other indications: household contacts and sex partners of persons with chronic hepatitis B virus (HBV) infection; clients and staff
members of institutions for persons with developmental disabilities; all clients of STD clinics; international travelers to countries with high or
intermediate prevalence of chronic HBV infection (a list of countries is available at
http://www.cdc.gov/travel/diseases.htm); and any adult seeking
protection
from HBV infection. Settings where hepatitis B vaccination is recommended for all adults: STD treatment facilities; HIV testing and
treatment facilities; facilities providing drug-abuse treatment and prevention services; health-care settings providing services for injection-drug users or
men who have sex with men; correctional facilities; end-stage renal disease programs and facilities for chronic hemodialysis patients; and
institutions and nonresidential daycare facilities for persons with developmental disabilities.
Special formulation indications: for adult patients
receiving hemodialysis and other immunocompromised adults, 1 dose of 40
µg/mL (Recombivax HB®) or 2 doses of 20
µg/mL (Engerix-B®).
10. Meningococcal vaccination. Medical
indications: adults with anatomic or functional asplenia, or terminal complement
component deficiencies. Other indications: first-year college students living in dormitories; microbiologists who are routinely exposed to isolates of
Neisseria meningitidis; military recruits; and persons who travel to or live in countries in which meningococcal disease is hyperendemic or epidemic
(e.g., the "meningitis belt" of sub-Saharan Africa during the dry season [December_June]), particularly if their contact with local populations will
be prolonged. Vaccination is required by the government of Saudi Arabia for all travelers to Mecca during the annual Hajj. Meningococcal
conjugate vaccine is preferred for adults with any of the preceding indications who are aged
<55 years, although meningococcal polysaccharide
vaccine (MPSV4) is an acceptable alternative. Revaccination after 5 years might be indicated for adults previously vaccinated with MPSV4 who remain
at high risk for infection (e.g., persons residing in areas in which disease is epidemic).
11. Selected conditions for which Haemophilus
influenzae type b (Hib) vaccine may be used.
Hib conjugate vaccines are licensed for children aged 6 weeks_71 months. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for
older children and adults with the chronic conditions associated with an increased risk for Hib disease. However, studies suggest good
immunogenicity in patients who have sickle cell disease, leukemia, or HIV infection or who have had splenectomies; administering vaccine to these patients is
not contraindicated.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
